| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Helix Holdings II LLC | 23% | 17,878,594 | Bihua Chen | 11 Aug 2025 | ||||
| BridgeBio Pharma LLC | 18% | 13,878,554 | BridgeBio Pharma LLC | 11 Aug 2025 | ||||
| Flynn James E | 6.2% | 4,885,446 | Deerfield Management Company, L.P. | 11 Aug 2025 | ||||
| BC Global Opportunities IX LP | 5.5% | $42,740,663 | 4,365,747 | BC Global Opportunities IX LP | 04 Sep 2025 | |||
| CITADEL ADVISORS LLC | 3.2% | $29,391,684 | 2,538,142 | Kenneth Griffin | 30 Sep 2025 | |||
| Adage Capital Management, L.P. | 1.9% | $17,226,651 | 1,487,621 | Adage Capital Management, L.P. | 30 Sep 2025 | |||
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.1% | $10,248,786 | 885,042 | T. Rowe Price Associates, Inc. | 30 Sep 2025 |
As of 31 Dec 2025, 52 institutional investors reported holding 57,897,060 shares of BridgeBio Oncology Therapeutics, Inc. - COMMON STOCK (BBOT). This represents 72% of the company’s total 80,458,364 outstanding shares.
The largest institutional shareholders of BridgeBio Oncology Therapeutics, Inc. - COMMON STOCK (BBOT) together control 70% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Cormorant Asset Management, LP | 22% | 17,878,594 | 0% | 13% | $223,839,997 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 6.1% | 4,885,446 | 0% | 0.78% | $61,165,784 |
| Omega Fund Management, LLC | 4.1% | 3,289,661 | 0% | 14% | $41,186,556 |
| WELLINGTON MANAGEMENT GROUP LLP | 3.6% | 2,907,003 | -1.8% | 0.01% | $36,395,678 |
| EcoR1 Capital, LLC | 3.5% | 2,823,126 | 0% | 1.6% | $35,345,538 |
| Alphabet Inc. | 3.5% | 2,823,126 | 0% | 1.4% | $35,345,538 |
| ENAVATE SCIENCES GP, LLC | 3.3% | 2,626,946 | 0% | 6.5% | $32,889,364 |
| CITADEL ADVISORS LLC | 3.1% | 2,530,324 | -0.31% | 0.02% | $31,679,656 |
| Paradigm Biocapital Advisors LP | 2.8% | 2,261,749 | +21% | 0.76% | $28,317,097 |
| BlackRock, Inc. | 2.6% | 2,084,837 | +1.8% | 0% | $26,102,158 |
| NOVO HOLDINGS A/S | 2.4% | 1,961,317 | 0% | 1.9% | $24,555,689 |
| Laurion Capital Management LP | 1.8% | 1,464,938 | +40% | 1.3% | $18,341,024 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.7% | 1,400,000 | -5.9% | 0.03% | $17,528,000 |
| EVENTIDE ASSET MANAGEMENT, LLC | 1.3% | 1,082,362 | 0% | 0.21% | $13,388,818 |
| Octagon Capital Advisors LP | 1.3% | 1,043,110 | 0% | 1.6% | $13,059,737 |
| ARMISTICE CAPITAL, LLC | 1.2% | 1,000,000 | +143% | 0.31% | $12,520,000 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1% | 803,134 | -9.3% | 0% | $10,056,000 |
| VANGUARD GROUP INC | 0.98% | 791,095 | +22% | 0% | $9,904,510 |
| Aisling Capital Management LP | 0.7% | 564,625 | 0% | 1.5% | $7,069,105 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.7% | 561,987 | +3.8% | 0% | $7,039,495 |
| Casdin Capital, LLC | 0.35% | 282,312 | 0% | 0.22% | $3,534,546 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.35% | 279,046 | -0.11% | 0% | $3,493,656 |
| MILLENNIUM MANAGEMENT LLC | 0.3% | 241,415 | -35% | 0% | $3,022,516 |
| FMR LLC | 0.3% | 240,300 | +48% | 0% | $3,008,556 |
| HighVista Strategies LLC | 0.28% | 229,263 | 0.74% | $2,870,372 |